FR23C1044I2 - PSMA BINDING AGENTS AND ITS USES - Google Patents
PSMA BINDING AGENTS AND ITS USESInfo
- Publication number
- FR23C1044I2 FR23C1044I2 FR23C1044C FR23C1044C FR23C1044I2 FR 23C1044 I2 FR23C1044 I2 FR 23C1044I2 FR 23C1044 C FR23C1044 C FR 23C1044C FR 23C1044 C FR23C1044 C FR 23C1044C FR 23C1044 I2 FR23C1044 I2 FR 23C1044I2
- Authority
- FR
- France
- Prior art keywords
- binding agents
- psma binding
- psma
- agents
- binding
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 title 1
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 title 1
- 239000011230 binding agent Substances 0.000 title 1
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/06—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton
- C07C275/16—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of an acyclic and saturated carbon skeleton being further substituted by carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/04—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms
- C07C275/18—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/61—Halogen atoms or nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/22—Tin compounds
- C07F7/2208—Compounds having tin linked only to carbon, hydrogen and/or halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Nuclear Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8546208P | 2008-08-01 | 2008-08-01 | |
US11179108P | 2008-11-06 | 2008-11-06 | |
PCT/US2009/052456 WO2010014933A2 (en) | 2008-08-01 | 2009-07-31 | Psma-binding agents and uses thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
FR23C1044I1 FR23C1044I1 (en) | 2023-12-29 |
FR23C1044I2 true FR23C1044I2 (en) | 2024-08-23 |
Family
ID=41610978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
FR23C1044C Active FR23C1044I2 (en) | 2008-08-01 | 2023-11-06 | PSMA BINDING AGENTS AND ITS USES |
Country Status (23)
Country | Link |
---|---|
US (6) | US8778305B2 (en) |
EP (3) | EP4089074A1 (en) |
JP (6) | JP5588441B2 (en) |
KR (1) | KR101664855B1 (en) |
CN (3) | CN107382846B (en) |
AU (1) | AU2009276423B2 (en) |
CA (2) | CA2732632C (en) |
CY (2) | CY1119367T1 (en) |
DK (2) | DK3222615T3 (en) |
ES (2) | ES2634894T3 (en) |
FI (1) | FIC20230033I1 (en) |
FR (1) | FR23C1044I2 (en) |
HK (1) | HK1247197A1 (en) |
HR (2) | HRP20220742T1 (en) |
HU (3) | HUE034027T2 (en) |
LT (2) | LT2318366T (en) |
NL (1) | NL301250I2 (en) |
NO (1) | NO2024006I1 (en) |
PL (2) | PL2318366T3 (en) |
PT (2) | PT2318366T (en) |
RU (1) | RU2494096C2 (en) |
SI (2) | SI2318366T1 (en) |
WO (1) | WO2010014933A2 (en) |
Families Citing this family (80)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2696627C (en) | 2007-08-17 | 2016-09-27 | Purdue Research Foundation | Psma binding ligand-linker conjugates and methods for using |
US9422234B2 (en) * | 2007-11-30 | 2016-08-23 | The Johns Hopkins University | Prostate specific membrane antigen (PSMA) targeted nanoparticles for therapy of prostate cancer |
US8855387B2 (en) | 2007-12-28 | 2014-10-07 | Exini Diagnostics Ab | System for detecting bone cancer metastases |
CA2732632C (en) * | 2008-08-01 | 2018-01-09 | The Johns Hopkins University | Psma-binding agents and uses thereof |
CN102714296A (en) | 2009-05-19 | 2012-10-03 | Aic布莱博公司 | Composite current collector and method of forming the same |
US9951324B2 (en) | 2010-02-25 | 2018-04-24 | Purdue Research Foundation | PSMA binding ligand-linker conjugates and methods for using |
US10011632B2 (en) | 2011-08-22 | 2018-07-03 | Siemens Medical Solutions Usa, Inc. | PSMA imaging agents |
US20130116404A1 (en) | 2011-11-08 | 2013-05-09 | Case Western Reserve University | Targeted non-invasive imaging probes of egfr expressing cells |
ES2941937T3 (en) * | 2011-11-30 | 2023-05-26 | Univ Johns Hopkins | Compound targeting PSMA and its uses |
US20140065070A1 (en) * | 2012-08-28 | 2014-03-06 | Mcmaster University | Methods of preparing triazole-containing radioiodinated compounds |
US9636413B2 (en) * | 2012-11-15 | 2017-05-02 | Endocyte, Inc. | Conjugates for treating diseases caused by PSMA expressing cells |
DK2970345T3 (en) * | 2013-03-15 | 2019-08-26 | Cancer Targeted Tech Llc | 18F-LABELED PSMA TARGETED PET CONTRACTORS |
WO2015057692A1 (en) | 2013-10-14 | 2015-04-23 | The Johns Hopkins University | Prostate-specific membrane antigen-targeted photosensitizers for photodynamic therapy |
PL4095130T3 (en) | 2013-10-18 | 2024-06-10 | Novartis Ag | Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
JP6292568B2 (en) * | 2013-11-06 | 2018-03-14 | 国立大学法人京都大学 | Urea derivative compound and radiopharmaceutical containing the same |
US9713649B2 (en) | 2014-01-24 | 2017-07-25 | The Cleveland Clinic Foundation | PSMA-targeting imaging agents |
WO2015153772A2 (en) * | 2014-04-01 | 2015-10-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Zirconium-89 oxine complex as a cell labeling agent for positron emission tomography |
EP3183236B1 (en) | 2014-08-24 | 2022-04-20 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften | Method for the production of 18f-labeled active esters and their application exemplified by the preparation of a psma-specific pet-tracer |
EP2993171A1 (en) * | 2014-09-04 | 2016-03-09 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for the production of 18F-labeled PSMA-specific PET-tracers |
EP3209336B1 (en) | 2014-10-20 | 2019-12-11 | Deutsches Krebsforschungszentrum | 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer |
EP3011976A1 (en) * | 2014-10-20 | 2016-04-27 | Deutsches Krebsforschungszentrum | 18F-tagged inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents |
US10736974B2 (en) | 2014-10-22 | 2020-08-11 | The Johns Hopkins University | Scaffolds and multifunctional intermediates for imaging PSMA and cancer therapy |
US10188759B2 (en) | 2015-01-07 | 2019-01-29 | Endocyte, Inc. | Conjugates for imaging |
US20180338910A1 (en) * | 2015-01-09 | 2018-11-29 | The Johns Hopkins University | Intranasal administration of glutamate carboxypeptidase (gcp-ii) inhibitors |
US10869940B2 (en) | 2015-06-12 | 2020-12-22 | The Board Of Trustees Of The Leland Stanford Junior University | Targeted photoacoustic compounds, formulations, and uses thereof |
WO2017029399A1 (en) * | 2015-08-20 | 2017-02-23 | Universität Zu Köln | Pain tracking by pet-imaging (pain-trap) |
EP3805250A1 (en) | 2015-09-30 | 2021-04-14 | Deutsches Krebsforschungszentrum | Improved 18f - tagged inhibitors of prostate specific membrane antigen (psma) and their use as imaging agents for prostate cancer |
US20200231614A1 (en) * | 2015-10-22 | 2020-07-23 | The Johns Hopkins University | Psma targeted radiohalogenated ureas for cancer radiotherapy |
KR101639599B1 (en) | 2015-11-09 | 2016-07-14 | 서울대학교산학협력단 | Peptide thiourea derivatives, their radioisotope labeled compounds and pharmaceutical composition for treatment or diagnosis of prostate cancer comprising the same as an active ingredient |
CA3049470A1 (en) | 2016-01-10 | 2017-07-13 | The University Of British Columbia | 18/19f-labelled compounds which target the prostate specific membrane antigen |
KR102558962B1 (en) * | 2016-06-10 | 2023-07-21 | 더 존스 홉킨스 유니버시티 | Improved synthesis of radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [ 18 F]DCFPyL |
KR102513698B1 (en) * | 2016-06-23 | 2023-03-23 | 코넬 유니버시티 | Dual targeting constructs for influencing tumor killing |
US10806806B2 (en) | 2016-06-23 | 2020-10-20 | Cornell University | Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies |
US10340046B2 (en) | 2016-10-27 | 2019-07-02 | Progenics Pharmaceuticals, Inc. | Network for medical image analysis, decision support system, and related graphical user interface (GUI) applications |
CN110167554B (en) * | 2016-11-17 | 2023-05-23 | 思路迪(北京)医药科技有限公司 | Compound with anticancer effect and preparation method and application thereof |
DE102016122273B4 (en) * | 2016-11-18 | 2018-06-21 | Abx Advanced Biochemical Compounds Gmbh | Precursors for radiofluorination |
CN117563022A (en) | 2017-04-05 | 2024-02-20 | 康奈尔大学 | Trifunctional constructs with tunable pharmacokinetics for imaging and anti-tumor therapy |
JP7284707B2 (en) * | 2017-04-07 | 2023-05-31 | ジュノー セラピューティクス インコーポレイテッド | Engineered Cells Expressing Prostate-Specific Membrane Antigen (PSMA) or Modified Forms Thereof and Related Methods |
US11491247B2 (en) | 2017-05-02 | 2022-11-08 | Cornell University | Methods and reagents for tumor targeting with greater efficacy and less toxicity |
WO2018236115A1 (en) | 2017-06-19 | 2018-12-27 | (주)퓨쳐켐 | 18f-labelled compound for prostate cancer diagnosis, and use thereof |
SG11201911602RA (en) | 2017-06-19 | 2020-01-30 | Futurechem Co Ltd | 18f-labelled compound for prostate cancer diagnosis, and use thereof |
EA202090776A1 (en) * | 2017-10-23 | 2020-07-27 | Дзе Джонс Хопкинс Юниверсити | VISUALIZING AND RADIOTHERAPY AGENTS TARGETED ON FIBROBLAST-ACTIVATING PROTEIN ALPHA (FAPALPHA) |
CR20200241A (en) * | 2017-12-11 | 2020-09-21 | Univ Muenchen Tech | Psma ligands for imaging and endoradiotherapy |
US10973486B2 (en) | 2018-01-08 | 2021-04-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
WO2019136349A2 (en) | 2018-01-08 | 2019-07-11 | Progenics Pharmaceuticals, Inc. | Systems and methods for rapid neural network-based image segmentation and radiopharmaceutical uptake determination |
CA3090495A1 (en) * | 2018-02-06 | 2019-08-15 | The Johns Hopkins University | Psma targeted radiohalogenated urea-polyaminocarboxylates for cancer radiotherapy |
WO2019183633A1 (en) | 2018-03-23 | 2019-09-26 | Case Western Reserve Univeristy | Psma targeted conjugate compounds and uses thereof |
CN109160896B (en) * | 2018-05-16 | 2021-06-25 | 上海如絮生物科技有限公司 | Hydrophilic pyridine compound intermediate and preparation method thereof |
CN109160899B (en) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | Hydrophilic pyridine compound, intermediate, preparation method and application thereof |
CN109160898B (en) * | 2018-05-16 | 2021-06-04 | 上海如絮生物科技有限公司 | Hydrophilic pyridine compound intermediate and preparation method thereof |
US20210338846A1 (en) * | 2018-07-30 | 2021-11-04 | The Johns Hopkins University | Competitive prostate-specific membrane antigen (psma) binding agents for reduction of non-target organ uptake of radiolabeled psma inhibitors for psma positive tumor imaging and radiopharmaceutical therapy |
CN113164450A (en) | 2018-10-11 | 2021-07-23 | 普罗热尼奇制药公司 | Combination therapy for the treatment of metastatic prostate cancer |
RU2697519C1 (en) * | 2018-10-15 | 2019-08-15 | Общество с ограниченной ответственностью "Изварино Фарма" | Peptide agent comprising a psma-binding ligand based on a urea derivative, a method for production thereof and use thereof for preparing a conjugate with a drug and diagnostic agent |
KR102403970B1 (en) | 2018-12-27 | 2022-05-31 | (주)퓨쳐켐 | Carboxylic acid-having compounds for PSMA-targeting and use thereof |
WO2020144134A1 (en) | 2019-01-07 | 2020-07-16 | Exini Diagnostics Ab | Systems and methods for platform agnostic whole body image segmentation |
PL239934B1 (en) * | 2019-04-12 | 2022-01-31 | Narodowe Centrum Badan Jadrowych Osrodek Radioizotopow Polatom | Derivatives of PSMA inhibitors for ⁹⁹ᵐTc labelling by HYNIC, radiopharmaceutical kit, radiopharmaceutical preparations and their use in the diagnosis of prostate cancer |
CA3134745A1 (en) | 2019-04-24 | 2020-10-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for interactive adjustment of intensity windowing in nuclear medicine images |
CA3136127A1 (en) | 2019-04-24 | 2020-10-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for automated and interactive analysis of bone scan images for detection of metastases |
BR112021025810A2 (en) | 2019-06-21 | 2022-05-10 | Provincial Health Services Authority | Radiolabeled compounds targeting prostate-specific membrane antigen |
RU2713151C1 (en) * | 2019-07-02 | 2020-02-04 | Общество с ограниченной ответственностью "Изварино Фарма" | Conjugate of a fluorescent dye with a peptide substance which contains a psma-binding ligand based on a urea derivative for visualizing cells expressing psma, a method for production thereof and use thereof |
EP4021455A4 (en) * | 2019-08-30 | 2023-10-04 | Memorial Sloan Kettering Cancer Center | Novel theranostic agents for psma positive cancers |
US11900597B2 (en) | 2019-09-27 | 2024-02-13 | Progenics Pharmaceuticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
US11564621B2 (en) | 2019-09-27 | 2023-01-31 | Progenies Pharmacenticals, Inc. | Systems and methods for artificial intelligence-based image analysis for cancer assessment |
US11544407B1 (en) | 2019-09-27 | 2023-01-03 | Progenics Pharmaceuticals, Inc. | Systems and methods for secure cloud-based medical image upload and processing |
US11321844B2 (en) | 2020-04-23 | 2022-05-03 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
US11386988B2 (en) | 2020-04-23 | 2022-07-12 | Exini Diagnostics Ab | Systems and methods for deep-learning-based segmentation of composite images |
CN111548305B (en) * | 2020-05-12 | 2021-08-31 | 北京师范大学 | Quinoline compound for targeting PSMA (patterned middle molecular weight ligands) and preparation method thereof |
CA3163190A1 (en) | 2020-07-06 | 2022-01-13 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
US11721428B2 (en) | 2020-07-06 | 2023-08-08 | Exini Diagnostics Ab | Systems and methods for artificial intelligence-based image analysis for detection and characterization of lesions |
US20230406847A1 (en) | 2020-11-12 | 2023-12-21 | Abx Advanced Biochemical Compounds Gmbh | Ligands of prostate specific membrane antigen (psma) containing heteroaromatic linker building blocks |
CN114685599A (en) * | 2020-12-30 | 2022-07-01 | 南京江原安迪科正电子研究发展有限公司 | PSMA (patterned beam mosaic Virus inhibitor) targeted inhibitor, radionuclide-labeled PSMA targeted inhibitor, preparation method and application |
MX2024001424A (en) | 2021-07-30 | 2024-05-20 | Univ Osaka | Radiolabeled compound and use thereof. |
TW202324443A (en) | 2021-10-08 | 2023-06-16 | 瑞典商艾西尼診斷公司 | Systems and methods for automated identification and classification of lesions in local lymph and distant metastases |
EP4429654A1 (en) | 2021-11-09 | 2024-09-18 | Case Western Reserve University | Psma targeted conjugate compounds and uses thereof |
US20230410985A1 (en) | 2022-06-08 | 2023-12-21 | Exini Diagnostics Ab | Systems and methods for assessing disease burden and progression |
WO2024150132A1 (en) | 2023-01-10 | 2024-07-18 | Sun Pharma Advanced Research Company Limited | Ligand-drug conjugates |
US20240285248A1 (en) | 2023-02-13 | 2024-08-29 | Progenics Pharmaceuticals, Inc. | Systems and methods for predicting biochemical progression free survival in prostate cancer patients |
CN116217505B (en) * | 2023-03-17 | 2024-10-01 | 南京医科大学 | Novel marker targeting agents for diagnosis or treatment of cancers expressing prostate specific membrane antigen |
US20240354940A1 (en) | 2023-04-07 | 2024-10-24 | Progenics Pharmaceuticals, Inc. | Systems and methods for facilitating lesion inspection and analysis |
CN117670883B (en) * | 2024-01-31 | 2024-05-07 | 中国医学科学院北京协和医院 | Method, equipment and system for identifying high-low-level bladder cancer |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2233269C2 (en) * | 1998-11-02 | 2004-07-27 | Авентис Фарма Лимитед | Substituted anilides, pharmaceutical composition and method for treatment |
JP3750494B2 (en) | 1999-08-31 | 2006-03-01 | 松下電器産業株式会社 | Semiconductor device |
WO2006093991A1 (en) * | 2005-03-02 | 2006-09-08 | The Cleveland Clinic Foundation | Compounds which bind psma and uses thereof |
PT2097111E (en) | 2006-11-08 | 2015-11-03 | Molecular Insight Pharm Inc | Heterodimers of glutamic acid |
EP2921482B1 (en) * | 2007-06-26 | 2018-09-05 | The Johns Hopkins University | Labeled inhibitors of prostate-specific membrane antigen (psma), biological evaluation, and use as imaging agents |
ES2632052T3 (en) * | 2007-09-28 | 2017-09-08 | Pfizer Inc. | Addressing to cancer cells using nanoparticles |
CA2732632C (en) * | 2008-08-01 | 2018-01-09 | The Johns Hopkins University | Psma-binding agents and uses thereof |
GB0905438D0 (en) | 2009-03-30 | 2009-05-13 | Ge Healthcare Ltd | Radiolabelling reagents and methods |
KR102558962B1 (en) * | 2016-06-10 | 2023-07-21 | 더 존스 홉킨스 유니버시티 | Improved synthesis of radiolabeled prostate-specific membrane antigen (PSMA) inhibitor [ 18 F]DCFPyL |
-
2009
- 2009-07-31 CA CA2732632A patent/CA2732632C/en active Active
- 2009-07-31 WO PCT/US2009/052456 patent/WO2010014933A2/en active Application Filing
- 2009-07-31 HU HUE09803670A patent/HUE034027T2/en unknown
- 2009-07-31 CN CN201710536671.3A patent/CN107382846B/en active Active
- 2009-07-31 KR KR1020117004960A patent/KR101664855B1/en active IP Right Grant
- 2009-07-31 CA CA2987744A patent/CA2987744C/en active Active
- 2009-07-31 EP EP22163541.0A patent/EP4089074A1/en active Pending
- 2009-07-31 CN CN202110689899.2A patent/CN113563262A/en active Pending
- 2009-07-31 SI SI200931704T patent/SI2318366T1/en unknown
- 2009-07-31 EP EP09803670.0A patent/EP2318366B1/en active Active
- 2009-07-31 RU RU2011107752/04A patent/RU2494096C2/en active
- 2009-07-31 PT PT98036700T patent/PT2318366T/en unknown
- 2009-07-31 JP JP2011521362A patent/JP5588441B2/en active Active
- 2009-07-31 PL PL09803670T patent/PL2318366T3/en unknown
- 2009-07-31 PL PL17167057.3T patent/PL3222615T3/en unknown
- 2009-07-31 EP EP17167057.3A patent/EP3222615B1/en active Active
- 2009-07-31 HU HUE17167057A patent/HUE059436T2/en unknown
- 2009-07-31 DK DK17167057.3T patent/DK3222615T3/en active
- 2009-07-31 HR HRP20220742TT patent/HRP20220742T1/en unknown
- 2009-07-31 LT LTEP09803670.0T patent/LT2318366T/en unknown
- 2009-07-31 SI SI200932167T patent/SI3222615T1/en unknown
- 2009-07-31 CN CN200980139135.3A patent/CN102171187B/en active Active
- 2009-07-31 ES ES09803670.0T patent/ES2634894T3/en active Active
- 2009-07-31 PT PT171670573T patent/PT3222615T/en unknown
- 2009-07-31 AU AU2009276423A patent/AU2009276423B2/en active Active
- 2009-07-31 DK DK09803670.0T patent/DK2318366T3/en active
- 2009-07-31 US US13/057,044 patent/US8778305B2/en active Active
- 2009-07-31 LT LTEP17167057.3T patent/LT3222615T/en unknown
- 2009-07-31 ES ES17167057T patent/ES2914593T3/en active Active
-
2012
- 2012-02-27 HK HK18106684.8A patent/HK1247197A1/en unknown
-
2014
- 2014-03-14 US US14/211,683 patent/US9226981B2/en active Active
- 2014-07-25 JP JP2014152130A patent/JP5806765B2/en active Active
-
2015
- 2015-09-04 JP JP2015174731A patent/JP6030724B2/en active Active
-
2016
- 2016-01-04 US US14/987,032 patent/US9861713B2/en active Active
- 2016-10-20 JP JP2016206120A patent/JP6524046B2/en active Active
-
2017
- 2017-07-21 HR HRP20171133TT patent/HRP20171133T1/en unknown
- 2017-07-31 CY CY20171100825T patent/CY1119367T1/en unknown
-
2018
- 2018-01-08 US US15/864,236 patent/US10500292B2/en active Active
- 2018-11-26 JP JP2018220353A patent/JP7277113B2/en active Active
-
2019
- 2019-11-05 US US16/674,089 patent/US20200282083A1/en not_active Abandoned
-
2021
- 2021-01-28 JP JP2021012046A patent/JP7219497B2/en active Active
- 2021-04-22 US US17/237,850 patent/US12070513B2/en active Active
-
2023
- 2023-11-02 FI FIC20230033C patent/FIC20230033I1/en unknown
- 2023-11-03 CY CY2023024C patent/CY2023024I1/en unknown
- 2023-11-06 FR FR23C1044C patent/FR23C1044I2/en active Active
- 2023-11-14 HU HUS2300039C patent/HUS2300039I1/en unknown
- 2023-11-15 NL NL301250C patent/NL301250I2/en unknown
-
2024
- 2024-02-01 NO NO2024006C patent/NO2024006I1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
FR23C1044I2 (en) | PSMA BINDING AGENTS AND ITS USES | |
LTC2379594I2 (en) | Human CGRP receptor binding antibodies | |
CY2019004I1 (en) | MODIFIED ANTI-IL-23P19 ANTIBODIES | |
BRPI0908158A2 (en) | Issuer | |
BRPI0920406A2 (en) | termination devices and related methods. | |
BRPI0912198A2 (en) | anti-fn14 antibodies and uses thereof | |
BRPI0923191A2 (en) | Modified glycan related methods | |
EP2334330A4 (en) | Anti-cd147 antibodies, methods, and uses | |
BRPI0913961A2 (en) | damping device | |
DK2133652T3 (en) | MINE DEVICE | |
DE602009000028D1 (en) | damping force | |
DK2325662T3 (en) | MULTI-READING AND MULTI-READING ANALYZER | |
BRPI0819297A2 (en) | Dehydration Systems and Methods | |
DE502007001053D1 (en) | pressing device | |
FI20055589A0 (en) | emulation device | |
DE102007006050B8 (en) | connecting device | |
SE0802075L (en) | Card connection | |
FR2911438B1 (en) | SUSPENSION DEVICE | |
BRPI0908794A2 (en) | Railroad Crossroads Configuration | |
ES1068038Y (en) | PRACTICABLE BINDING DEVICE | |
FR2938787B1 (en) | COMPRESSION DEVICE | |
FR2936174B1 (en) | QUENOUILLE BUFFER | |
ES1063044Y (en) | CITRUS EXPRESSING DEVICE | |
FR2912170B1 (en) | ISOLOIR DEMONTABLE AND MODULABLE. | |
NL2002090C (en) | BINDING DEVICE. |